KRT18P46

Across TCGA pan-cancer cohorts, KRT18P46 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KRT18P46’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where KRT18P46 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT18P46 is over-expressed in tumor, although a few such as LIHC show the opposite, repressed pattern.

LUAD, BRCA, and STAD are the cancer types where KRT18P46 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P46 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	+0.029	.024	5	view →
BRCA	All	All	+0.009	.037	4	view →
STAD	All	All	+0.028	.014	2	view →
KIRC	Male	All	+0.009	.026	2	view →
LIHC	Female	All	−0.008	.037	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

KRT18P46–LUAD

Open the LUAD breakdown →